Sign Out
No interaction studies have been performed.
Experience with use of onasemnogene abeparvovec in patients receiving hepatotoxic medicinal products or using hepatotoxic substances is limited. Safety of onasemnogene abeparvovec in these patients have not been established.
Experience with use of concomitant 5q SMA targeting agents is limited.
Vaccinations: Where feasible, the patient's vaccination schedule should be adjusted to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion (see Dosage & Administration and Precautions). Seasonal RSV prophylaxis is recommended (see Precautions). Live vaccines, such as MMR and varicella, should not be administered to patients on an immunosuppressive steroid dose (i.e., ≥2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisolone or equivalent).
Continue with Google